Glidiab MV
Glidiab MV: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Glidiab MV
ATX code: A10BB09
Active ingredient: Gliclazid (Gliclazide)
Manufacturer: Akrikhin AO (Russia)
Description and photo update: 2018-24-10
Prices in pharmacies: from 112 rubles.
Buy
Glidiab MB is an oral hypoglycemic drug of the second generation sulfonylurea group.
Release form and composition
The dosage form of Glidiab MB is modified-release tablets: flat-cylindrical, white with a creamy shade or white, with a bevel, marbling is permissible (10 pcs. In blisters, in a cardboard box 3 or 6 packages).
Composition of 1 tablet:
- active substance: gliclazide - 30 mg;
- auxiliary components: microcrystalline cellulose - 123 mg; hypromellose - 44 mg; magnesium stearate - 2 mg; colloidal silicon dioxide - 1 mg.
Pharmacological properties
Pharmacodynamics
Glidiab MV belongs to the number of oral hypoglycemic drugs. The active ingredient is gliclazide, a derivative of II generation sulfonylurea.
The main effects of gliclazide:
- stimulation of insulin secretion by β-cells of the pancreas;
- increased sensitivity of peripheral tissues to insulin;
- restoration of the early peak of insulin secretion (which distinguishes Glidiab MV from other sulfonylurea derivatives, which have an effect to a greater extent during the second stage of secretion);
- decrease in the interval from the moment of eating to the beginning of insulin secretion;
- stimulation of the activity of intracellular enzymes - muscle glycogen synthetase;
- increased insulin-secretory action of glucose;
- decrease in postprandial increase in glucose levels;
- improvement of microcirculation, which manifests itself as a decrease in adhesion and aggregation of platelets, normalization of vascular permeability, prevention of the development of atherosclerosis and microthrombosis, restoration of physiological parietal fibrinolysis;
- slowing down the development of diabetic retinopathy at the nonproliferative stage; against the background of long-term use in diabetic nephropathy leads to a significant decrease in the severity of proteinuria;
- decreased sensitivity of vascular receptors to adrenaline.
Glidiab MV does not lead to an increase in body weight, since it has a predominant effect on the early peak of insulin secretion and does not cause hyperinsulinemia. In obese patients, with an appropriate diet, therapy promotes weight loss.
Pharmacokinetics
Gliclazide after oral administration is almost completely absorbed from the gastrointestinal tract. Its plasma concentration increases gradually and reaches a maximum within 6–12 hours. Food intake has no effect on the absorption of the substance.
With a daily intake of a single dose of Glidiab MB, an effective therapeutic plasma concentration of gliclazide is provided for 24 hours.
Plasma protein binding is approximately 95%.
Metabolism occurs in the liver with the subsequent formation of inactive metabolites.
T 1/2 (half-life) is approximately 16 hours. It is excreted mainly by the kidneys in the form of metabolites; about 1% of the substance is excreted unchanged in the urine.
Indications for use
According to the instructions, Glidiab MB is prescribed for the treatment of type 2 diabetes mellitus in combination with diet therapy and moderate physical activity in case of ineffectiveness of the latter.
Also, the drug is used in patients with type 2 diabetes mellitus in order to prevent complications of diabetes mellitus to reduce the risk of macro- and microvascular complications (retinopathy, nephropathy, stroke, myocardial infarction) by intensive glycemic control.
Contraindications
Absolute:
- type 1 diabetes mellitus;
- diabetic ketoacidosis;
- diabetic coma / precoma;
- conditions that are accompanied by impaired absorption of food, the occurrence of hypoglycemia (infectious diseases);
- hyperosmolar coma;
- paresis of the stomach;
- leukopenia;
- severe hepatic / renal failure;
- intestinal obstruction;
- major surgical interventions, extensive trauma, burns and other conditions that require insulin therapy;
- combination therapy with miconazole, danazol or phenylbutazone;
- age up to 18 years;
- pregnancy and the period of breastfeeding;
- individual intolerance to any of the components of the drug, as well as sulfonamides and other sulfonylurea derivatives.
Relative (Glidiab MV is prescribed under medical supervision):
- febrile syndrome;
- alcoholism;
- unbalanced / irregular diet;
- pituitary / adrenal insufficiency;
- severe diseases of the cardiovascular system (including atherosclerosis, ischemic heart disease);
- renal / hepatic impairment;
- hypopituitarism;
- insufficiency of glucose-6-phosphate dehydrogenase;
- long-term use of glucocorticosteroids;
- diseases of the thyroid gland, proceeding with a violation of its function;
- elderly age.
Instructions for the use of Glidiab MB: method and dosage
Glidiab MV is taken orally, once a day with breakfast.
The dose of the drug is selected by the doctor individually based on the clinical manifestations of the disease, fasting glucose levels and 2 hours after eating.
The initial daily dose is 1 tablet. In the future, if necessary, the dose is increased with a break of at least 2 weeks. The maximum dose is 4 tablets per day.
It is possible to switch from Glidiab to Glidiab MV in a daily dose of 1–4 tablets.
Therapy can be combined with other hypoglycemic agents: biguanides, insulin or alpha-glucosidase inhibitors.
Side effects
- endocrine system: hypoglycemia (in cases of violation of the dosage regimen and inadequate diet) - headache, feeling of hunger, helplessness and fatigue, sweating, severe weakness, inattention, aggressiveness, irritability, anxiety, convulsions, shallow breathing, loss of consciousness, delayed reaction, impossibility focus, blurred vision, depression, aphasia, tremor, sensory disturbances, dizziness, bradycardia, loss of self-control, delirium, hypersomnia;
- hematopoietic system: thrombocytopenia, anemia, leukopenia;
- digestive system: dyspepsia (manifested in the form of nausea, diarrhea, a feeling of heaviness in the epigastrium), anorexia (its severity when taking Glidiab MV decreases with food), liver dysfunctions (manifested in the form of increased activity of hepatic transaminases, cholestatic jaundice);
- allergic reactions: itching, maculopapular rash, urticaria.
Overdose
The main symptoms: hypoglycemia is possible up to the development of hypoglycemic coma.
Therapy: if the patient is conscious, ingestion of easily digestible carbohydrates (sugar) is indicated; in case of loss of consciousness, a 40% solution of dextrose (glucose) is injected intravenously, glucagon in a dose of 1-2 mg intramuscularly. In order to avoid the re-development of hypoglycemia after the restoration of consciousness, the patient should be given food rich in easily digestible carbohydrates.
special instructions
During therapy, hypoglycemia may develop, sometimes in a prolonged / severe form (hospitalization and intravenous administration of dextrose solution for several days may be required).
The use of Glidiab CF is possible only if the patient regularly eats, including breakfast. It is very important to ensure that you maintain an adequate intake of carbohydrates in your diet to reduce the likelihood of hypoglycemia. In most cases, the development of hypoglycemia is observed with a low-calorie diet, after drinking alcohol and performing vigorous / prolonged physical exercises, and also while taking several hypoglycemic drugs at the same time.
Symptoms of hypoglycemia usually resolve after eating carbohydrate-rich foods (sweeteners do not help eliminate symptoms). According to the experience of using other sulfonylurea derivatives, it should be borne in mind that, despite the effective initial relief of this condition, hypoglycemia may recur. With a pronounced nature of the symptoms or their prolonged course, patients need emergency medical care, up to hospitalization, even with a temporary improvement in their condition after eating carbohydrate-rich food.
To reduce the risk of hypoglycemia, careful selection of drugs and their use regimen is required, and the patient should also be informed about the features of therapy.
An increased risk of hypoglycemia occurs in the following cases:
- inability / refusal of the patient (especially elderly patients) to comply with the doctor's prescriptions and control their condition;
- irregular / inadequate nutrition, skipping meals, dietary changes and fasting;
- imbalance between the amount of carbohydrates taken and physical activity;
- diseases of the thyroid gland, adrenal / pituitary insufficiency and some other endocrine disorders;
- overdose of Glidiab MB;
- severe liver failure;
- renal failure;
- combined use with certain drugs.
In patients with a deficiency of glucose-6-phosphate dehydrogenase, Glidiab MB can lead to the development of hemolytic anemia (before prescribing the drug, it is necessary to assess the possibility of using a hypoglycemic drug belonging to another group).
While taking Glidiab MB, glycemic control may be weakened in the following cases: trauma, fever, infectious diseases, or major surgical interventions (it may be necessary to stop using the drug and switch to insulin therapy).
After a long period of treatment in many patients, the effectiveness of Glidiab MB may decrease, which is probably associated with the progression of the underlying disease or a decrease in the therapeutic response to the drug. This phenomenon is secondary drug resistance, it must be distinguished from the primary one, in which therapy does not give the expected clinical effect from the moment of administration. Prior to diagnosing secondary drug resistance, an assessment of patient compliance with the prescribed diet and adequacy of dose selection should be performed.
To assess glycemic control, it is recommended to regularly determine the parameters of glycosylated hemoglobin and fasting blood glucose. Regular self-monitoring of blood glucose concentration is also advisable.
Influence on the ability to drive vehicles and complex mechanisms
While driving, patients should take into account the likelihood of developing hypoglycemia.
Application during pregnancy and lactation
Pregnancy and lactation are contraindications for taking Glidiab MB 30 mg.
In pregnant women, insulin is the drug of choice for the treatment of diabetes mellitus. There are no data on whether gliclazide passes into breast milk.
Pediatric use
Glidiab CF is not prescribed for patients under the age of 18.
With impaired renal function
- impaired renal function in severe course: therapy is contraindicated;
- impaired renal function: the drug is prescribed with caution.
For violations of liver function
- hepatic dysfunction in severe course: therapy is contraindicated;
- hepatic dysfunction: the drug is prescribed with caution.
Use in the elderly
Glidiab CF is prescribed with caution in elderly patients.
Drug interactions
Combinations in which blood glucose may increase (weakening of the action of gliclazide):
- danazol: the combination is not recommended; the drug has a diabetogenic effect; if it is impossible to replace it with another drug, the concentration of glucose in the blood should be monitored; during combined therapy and after its completion, the doctor can adjust the dose of Glidiab MB;
- chlorpromazine (in a daily dose of 100 mg): the combination requires caution, since there is an increase in the concentration of glucose in the blood and a decrease in insulin secretion; if it is impossible to replace it with another drug, the concentration of glucose in the blood should be monitored; during combined therapy and after its completion, the doctor can adjust the dose of Glidiab MB;
- tetracosactide and glucocorticosteroids (local / systemic use: intra-articular, rectal and external administration): the combination requires caution, since there is an increase in blood glucose concentration with the possible development of ketoacidosis; it is recommended to carefully monitor the concentration of glucose in the blood, especially at the beginning of therapy; during combined therapy and after its completion, the doctor can adjust the dose of Glidiab MB;
- salbutamol, ritodrin, terbutaline (intravenous): the combination requires caution;
- anticoagulants (in particular, warfarin): increasing the action of anticoagulants (their dose may need to be adjusted).
Combinations in which the risk of developing hypoglycemia increases (increased action of gliclazide):
- miconazole (systemic or topical application in the form of a gel on the mucous membranes of the oral cavity): the combination is contraindicated, since hypoglycemia may develop up to a coma;
- phenylbutazone (systemic administration): the combination is not recommended; if it is impossible to replace it with another drug, the concentration of glucose in the blood should be monitored; during combined therapy and after its completion, the doctor can adjust the dose of Glidiab MB;
- ethanol: the combination is not recommended, which is associated with increased hypoglycemia and the likelihood of developing hypoglycemic coma;
- Other hypoglycemic agents (insulin, alpha-glucosidase inhibitors, metformin, thiazolidinediones, inhibitors of dipeptidyl peptidase-4 agonists, glucagon-like peptide-1), non-steroidal anti-inflammatory drugs, fluconazole, beta-blockers, angiotensin converting enzyme inhibitors (captopril, enalapril), blockers of H 2 - histamine receptors, monoamine oxidase inhibitors, clarithromycin, sulfonamides: the combination requires caution.
Analogs
Analogs of Glidiab MB are: Diabeton MB, Diabeton MB, Gliclazid Canon, Glidiab, Gliclada, Diabetalong, Diabinax, Diabefarm.
Terms and conditions of storage
Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Glidiab MV
According to reviews, Glidiab MB is an effective drug used to lower blood glucose levels in type 2 diabetes. The best results can be achieved with diet and exercise advice. The development of adverse reactions is rarely reported.
Price for Glidiab MB in pharmacies
The approximate price for Glidiab MB 30 mg (60 tablets per pack) is 109-149 rubles.
Glidiab MV: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Glidiab MV 30 mg modified release tablets 60 pcs. 112 RUB Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
